Overview

A Long Term Safety Study Of Lersivirine For The Treatment Of HIV-1 Infection In Subjects Who Have Completed Treatment With Lersivirine In Studies A5271015 And A5271022

Status:
Terminated

Trial end date:
2013-04-01

Target enrollment:

Participant gender:

Summary

This is a study to assess long-term safety and efficacy of lersivirine in patients who have completed 96 weeks of treatment with lersivirine in studies A5271015 and A5271022.

Phase:

Phase 2

Details

Lead Sponsor:

Pfizer

Collaborator:

ViiV Healthcare

Treatments:

Efavirenz
Etravirine